We are live on
!
Find out more
SI
Sofinnova Investments Portfolio holdings
AUM
$2.63B
1-Year Est. Return
117.41%
This Fund
S&P 500
This Quarter
Est. Return
+35.61%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$582M
AUM Growth
–
Cap. Flow
+$600M
Cap. Flow
% of AUM
103.21%
Top 10 Holdings %
Top 10 Hldgs %
91.48%
Holding
54
New
54
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$139M |
| 2 |
NCNA
NuCana
NCNA
|
+$88.6M |
| 3 |
OBSV
ObsEva SA Ordinary Shares
OBSV
|
+$58.3M |
| 4 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$46.7M |
| 5 |
PDS Biotechnology
PDSB
|
+$38.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma A/S
ASND
$16.7B
| $162M | 27.87% |
+2,479,514
| New | +$139M |
|
|
NCNA
2
NuCana
NCNA
$5.37M
| $88.3M | 15.17% |
+933
| New | +$88.6M |
|
|
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $64.1M | 11.02% |
+4,749,623
| New | +$58.3M |
|
|
BOLD
4
DELISTED
Audentes Therapeutics, Inc
BOLD
| $41.5M | 7.13% |
+1,380,303
| New | +$46.7M |
|
|
MRUS
5
DELISTED
Merus
MRUS
| $36.3M | 6.25% |
+1,961,039
| New | +$35.6M |
|
|
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $32M | 5.51% |
+481,270
| New | +$27.8M |
|
7
Coherus Oncology
CHRS
$217M
| $32M | 5.49% |
+2,893,221
| New | +$31.7M |
|
8
Natera
NTRA
$37.5B
| $28.7M | 4.94% |
+3,100,560
| New | +$30.4M |
|
9
Aclaris Therapeutics
ACRS
$730M
| $27M | 4.64% |
+1,539,480
| New | +$32.6M |
|
|
APLS
10
DELISTED
Apellis Pharmaceuticals
APLS
| $20.2M | 3.46% |
+911,752
| New | +$17.9M |
|
|
AMRN
11
Amarin Corp
AMRN
$284M
| $10M | 1.72% |
+166,079
| New | +$12.3M |
|
12
Ocugen
OCGN
$410M
| $5.71M | 0.98% |
+34,617
| New | +$5.52M |
|
|
SYBX
13
DELISTED
Synlogic
SYBX
| $5.39M | 0.93% |
+38,331
| New | +$5.94M |
|
|
ATYR
14
aTyr Pharma
ATYR
$46.4M
| $4.95M | 0.85% |
+133,295
| New | +$6.25M |
|
|
15
PDS Biotechnology
PDSB
$38.1M
| $3.37M | 0.58% |
+142,636
| New | +$38.4M |
|
|
CHMA
16
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $2.44M | 0.42% |
+1,630,221
| New | +$2.58M |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $1.58M | 0.27% |
+9,379
| New | +$1.57M |
|
|
CYTO
18
DELISTED
Altamira Therapeutics Ltd
CYTO
| $1.25M | 0.22% |
+98
| New | +$2.62M |
|
|
ALXN
19
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.02M | 0.17% |
+9,126
| New | +$1.09M |
|
20
Bristol-Myers Squibb
BMY
$127B
| $951K | 0.16% |
+15,033
| New | +$967K |
|
21
Heron Therapeutics
HRTX
$86.3M
| $832K | 0.14% |
+30,133
| New | +$684K |
|
|
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
| $794K | 0.14% |
+186,774
| New | +$799K |
|
23
AstraZeneca
AZN
$263B
| $763K | 0.13% |
+10,916
| New | +$756K |
|
24
PTC Therapeutics
PTCT
$6.37B
| $696K | 0.12% |
+25,729
| New | +$652K |
|
|
AIMT
25
DELISTED
Aimmune Therapeutics
AIMT
| $646K | 0.11% |
+20,308
| New | +$715K |
|
Similar funds
WWM
ACI
LOAMS
IA
WCA
ACM
NIG
WBG
Sofinnova Investments's Q1 2018 Portfolio in Review
Q1 2018 is the first quarter with a 13F filing on record for Sofinnova Investments, which disclosed 54 positions worth $582M. Its ten largest holdings account for 91% of the portfolio.
Its largest position is Ascendis Pharma A/S: 2,479,514 shares worth $162M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets.
- Sofinnova Investments's largest Q1 2018 buy was Ascendis Pharma A/S: 2,479,514 shares worth $162M.
- Sofinnova Investments's ten largest holdings make up 91% of its $582M portfolio in Q1 2018.
- Sofinnova Investments disclosed 54 positions in Q1 2018, its first 13F filing on record.
Based on Sofinnova Investments's 13F filing for Q1 2018, filed 15 May 2018.